KDR and gastric cancer: Apatinib, a small molecule tyrosine kinase inhibitor that selectively binds to VEGFR-2, was developed in China and was indicated for advanced and metastatic GC.[5] A phase III trial showed that apatinib rather than placebo significantly improved overall survival and progression-free survival (PFS) in patients with advanced GC after 2 lines of previous chemotherapy.